Books and Book Chapters

      Developing Network-Based Systems Toxicology by Combining Transcriptomics Data with Literature Mining and Multiscale Quantitative Modeling

      Sewer, A.; Talikka, M.; Martin, F.; Hoeng, J.; Peitsch, M. C.
      Date published
      Jun 20, 2018
      DOI
      10.5772/intechopen.75970
      ISBN
      978-1-78923-269-1
      Published in
      Bioinformatics in the Era of Post Genomics and Big Data
      Editors
      Abdurakhmonov, I. Y.
      Link to publication
      Topic
      Summary

      We describe how the genome-wide transcriptional profiling can be used in network-based systems toxicology, an approach leveraging biological networks for assessing the health risks of exposure to chemical compounds. Driven by the technological advances changing the ways in which data are generated, systems toxicology has allowed traditional toxicity endpoints to be enhanced with far deeper levels of analysis. In combination, new experimental and computational methods have offered the potential for more effective, efficient, and reliable toxicological testing strategies. We illustrate these advances by the “network perturbation amplitude” methodology that quantifies the effects of exposure treatments on biological mechanisms represented by causal networks. We also describe recent developments in the assembly of high-quality causal biological networks using crowdsourcing and text-mining approaches. We further show how network-based approaches can be integrated into the multiscale modeling framework of response to toxicological exposure. Finally, we combine biological knowledge assembly and multiscale modeling to report on the promising developments of the “quantitative adverse outcome pathway” concept, which spans multiple levels of biological organization, from molecules to population, and has direct relevance in the context of the “Toxicity Testing in the 21st century” vision of the US National Research Council.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.